ESR1 and breast cancer: Of patients with new breast cancer diagnoses, approximately 5%–10% present with metastatic breast cancer (mBC), and nearly 30% of patients will progress to mBC over the course of their disease, with this risk being particularly pronounced in ER-positive tumors (2,3,5,6).